⭐ Start off 2025 with a powerful boost to your portfolio: January’s freshest AI-picked sharesUnlock shares

Philips, Accenture test brain-controlled system for ALS patients

Published 05/08/2014, 19:05
Philips, Accenture test brain-controlled system for ALS patients

By Christina Farr SAN FRANCISCO (Reuters) - The Netherlands' Royal Philips and IT consultancy Accenture are developing software to help people with neurodegenerative diseases like amyotrophic lateral sclerosis, commonly known as Lou Gehrig's disease, live more independently.

The companies said they have built a trial application that lets patients with ALS, a disease that diminishes muscle action, issue "brain commands" to turn lights on and off or send an alert to a doctor.

The software works by connecting a wireless headset developed by Emotiv, a San Francisco-based startup, to a wearable device. Emotiv says its headset can read brain waves and translate them into readable data, which is then used to issue commands to Philips' existing suite of connected products, such as "smart" TVs and lighting systems.

Wearers also can issue commands via their voice or eyes, and the app lets patients store pre-recorded messages in their own voice.

Accenture and Philips jointly developed the software that connects the various technologies.

It marks the latest in a string of partnerships between information technology and medical firms to develop products for people with chronic conditions. In July, Google struck a deal with Swiss drug maker Novartis to develop a smart contact lens that can monitor blood-sugar levels, which would particularly be useful to diabetics.

Accenture and Philips stress their app is a "proof of concept" but they said they have tested it with patients. They remain open to conversations with other consumer technology providers, like Apple and Google, and are seeking partnerships with caregiver associations.

"We are looking for our next set of partners," Thibaut Sevestre, who heads innovation for Philips' IT architecture and platforms, said in an interview with Reuters.

"Patients find that they can do less and less by themselves, until they are completely paralysed," Sevestre added. "So we asked, how can we help them regain control?"

The app is not designed as a monitoring tool that can inform doctors of a patient's current state. Instead, Sevestre said it aimed to give people back "some capabilities they've lost." In the later stages of ALS, people will sometimes be rendered completely paralysed but retain brain functions.

The project kicked off in May after several Accenture employees pitched the idea, but its announcement was delayed several weeks. A key employee was among those who died in the downing of a Malaysia Airlines plane over eastern Ukraine in July.

Throughout the summer, Accenture conducted interviews and tests with ALS patients at its research lab in San Jose, California. Some 400,000 people suffer from the disease, but Accenture's chief technology officer, Paul Daugherty, said the goal is to adapt the application to a broad spectrum of patients.

The firms estimate their app can eventually benefit some 40 million people.

(Reporting by Christina Farr; Editing by Paul Simao)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.